NewAmsterdam Pharma Co N.V 6-K, filed Jan 11, 2023
NewAmsterdam Pharma Co N.V. (NAMS)
About this 6-K
NewAmsterdam Pharma Co N.V filed this 6-K on January 11, 2023.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of January 2023
Commission File Number: 001-41562
NewAmsterdam Pharma Company N.V.
(Exact name of registrant as specified in its charter)
Gooimeer 2-35
1411 DC Naarden
The Netherlands
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:
Form 20-F ☒ Form 40-F ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
On January 10, 2023, NewAmsterdam Pharma Company N.V. (the “Company”) received a notice from the Listing Qualifications Department of the Nasdaq Stock Market LLC, notifying the Company that its application to upgrade the listing of its ordinary shares from The Nasdaq Capital Market to The Nasdaq Global Market (the “Global Market”) has been approved. The Company’s ordinary shares will begin trading, with the same trading symbol, on the Global Market effective with the open of business on January 12, 2023.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| NewAmsterdam Pharma Company N.V. | ||||||
| January 11, 2023 | By: | /s/ David Topper | ||||
| Name: David Topper Title: Chief Financial Officer | ||||||